IL164281A0 - Epitope constructs comprising antigen presenting cell targeting mechanisms - Google Patents

Epitope constructs comprising antigen presenting cell targeting mechanisms

Info

Publication number
IL164281A0
IL164281A0 IL16428103A IL16428103A IL164281A0 IL 164281 A0 IL164281 A0 IL 164281A0 IL 16428103 A IL16428103 A IL 16428103A IL 16428103 A IL16428103 A IL 16428103A IL 164281 A0 IL164281 A0 IL 164281A0
Authority
IL
Israel
Prior art keywords
antigen presenting
presenting cell
cell targeting
epitope constructs
targeting mechanisms
Prior art date
Application number
IL16428103A
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of IL164281A0 publication Critical patent/IL164281A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL16428103A 2002-04-01 2003-04-01 Epitope constructs comprising antigen presenting cell targeting mechanisms IL164281A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36945402P 2002-04-01 2002-04-01
PCT/US2003/010033 WO2003084467A2 (en) 2002-04-01 2003-04-01 Epitope constructs comprising antigen presenting cell targeting mechanisms

Publications (1)

Publication Number Publication Date
IL164281A0 true IL164281A0 (en) 2005-12-18

Family

ID=28791953

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16428103A IL164281A0 (en) 2002-04-01 2003-04-01 Epitope constructs comprising antigen presenting cell targeting mechanisms

Country Status (6)

Country Link
JP (1) JP2005536987A (en)
AU (1) AU2003224819A1 (en)
CA (1) CA2478930A1 (en)
IL (1) IL164281A0 (en)
MX (1) MXPA04009554A (en)
WO (1) WO2003084467A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2448109A1 (en) * 2001-05-25 2002-12-05 Thomas Jefferson University Alternative splice forms of proteins as basis for multiple therapeutic modalities
US20030206916A1 (en) * 2002-05-03 2003-11-06 Rush-Presbyterian-St. Luke's Medical Center Immunogenic peptides
AU2003263767A1 (en) * 2002-07-03 2004-01-23 Aventis Pasteur Inc. Tumor antigens bfa4 and bcy1 for prevention and/or treatment of cancer
WO2004067716A2 (en) 2003-01-24 2004-08-12 Agensys, Inc. Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer
US7687465B2 (en) * 2003-04-11 2010-03-30 Kraeftens Bekaempelse Therapeutic cancer vaccine
GB0318247D0 (en) * 2003-08-05 2003-09-10 Royal Veterinary College Antigen delivery system
JP5869744B2 (en) 2005-03-23 2016-02-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Use of influenza virus and oil-in-water emulsion adjuvants to induce CD4 T cell and / or improved memory B cell responses
CA2615506A1 (en) * 2005-07-15 2007-01-25 Novartis Ag Pamps, pathogen associated molecular patterns
WO2007053956A1 (en) * 2005-11-14 2007-05-18 Universite Laval Cancer antigen mage-a9 and uses thereof
AU2007220042A1 (en) * 2006-02-27 2007-09-07 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
KR101696727B1 (en) 2006-07-17 2017-01-16 글락소스미스클라인 바이오로지칼즈 에스.에이. Influenza vaccine
EP2476435B1 (en) * 2006-08-11 2017-12-20 Life Sciences Research Partners VZW Immunogenic peptides and their use in immune disorders
CA2681132C (en) 2007-03-26 2018-05-01 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Prame derived peptides and immunogenic compositions comprising these
KR101167392B1 (en) * 2007-07-27 2012-07-19 이매틱스 바이오테크놀로지스 게엠베하 Composition of tumour-associated peptides and related anti-cancer vaccine
JP2012511033A (en) * 2008-12-08 2012-05-17 テゴファーム コーポレーション Masking ligand for reversible inhibition of multivalent compounds
FR2955773B1 (en) 2010-02-01 2017-05-26 Commissariat A L'energie Atomique MOLECULAR COMPLEX FOR TARGETING ANTIGENS TO ANTIGEN-PRESENTING CELLS AND ITS APPLICATIONS FOR VACCINATION
WO2012023033A2 (en) 2010-08-18 2012-02-23 Purdue Pharma L.P. Improved peptide immunogens
US9669091B2 (en) 2013-03-15 2017-06-06 Inovio Pharmaceuticals, Inc. Vaccines having an antigen and interleukin-23 as an adjuvant
WO2016057986A1 (en) * 2014-10-10 2016-04-14 The Trustees Of Columbia University In The City Of New York Tandem epitope constructs for presentation of cd4 and cd8 epitopes and uses thereof
US10238741B2 (en) 2014-10-10 2019-03-26 The Trustees Of Columbia University In The City Of New York Nucleic acid constructs for presentation of CD4 and CD8 epitopes, cellular transfection and uses thereof
WO2016196383A1 (en) * 2015-06-01 2016-12-08 Reber Genetics Co., Ltd. Vaccine compositions against porcine reproductive and respiratory syndrome and porcine circovirus associated diseases
US11674120B2 (en) 2016-03-22 2023-06-13 University Of Florida Research Foundation, Incorporated Methods, kits, and compositions for enhancing cellular therapy
WO2017177207A1 (en) * 2016-04-07 2017-10-12 Bostongene, Llc Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines
CN110996970A (en) 2017-06-02 2020-04-10 亚利桑那州立大学董事会 Method of creating personalized cancer vaccines
WO2019055618A1 (en) 2017-09-15 2019-03-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer

Also Published As

Publication number Publication date
WO2003084467A2 (en) 2003-10-16
MXPA04009554A (en) 2005-01-25
WO2003084467A3 (en) 2006-07-20
JP2005536987A (en) 2005-12-08
AU2003224819A1 (en) 2003-10-20
CA2478930A1 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
IL164281A0 (en) Epitope constructs comprising antigen presenting cell targeting mechanisms
HK1077226A1 (en) Human monoclonal antibodies against cd25
SI1740207T1 (en) Antigen delivery vectors and constructs
EP1633785A4 (en) Human monoclonal antibodies against bacillusanthracis protective antigen
AP2006003510A0 (en) Modified human IGF-1R antibodies.
EP1572131A4 (en) Antibody therapy
PL373886A1 (en) Neutralizing human anti-igfr antibody
EP1494693A4 (en) Cripto-specific antibodies
EP1550453A4 (en) Cancer antigen peptide preparation
EP1571909A4 (en) Optimized multi-epitope constructs and uses thereof
EP1461001A4 (en) Cancer-associated epitope
IL172511A0 (en) Specific human antibodies
AU2003255544A1 (en) Tumor specific oligosaccharide epitopes and use thereof
EP1597356A4 (en) Cultured cd14+ antigen presenting cells
GB0215287D0 (en) 5T4 antigen expression
AU2002365187A8 (en) Epitope synchronization in antigen presenting cells
EP1687398A4 (en) Hiv-dependent expression constructs and uses therefor
EP1594899A4 (en) Idiotypic vaccine
GB0305560D0 (en) Fuel formulations
GB0313064D0 (en) Mycobacterial vaccine
AU2002951847A0 (en) Antifungal antibody constructs
AU2003304720A1 (en) Peptides for targeting the prostate specific membrane antigen
GB0321288D0 (en) Structured polypeptide constructs
GB0325391D0 (en) Human monoclonal antibodies
GB0204988D0 (en) Padded envelope